Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 187 participants.
Also called NCT01398592
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 187 participants
- Sponsor
- Registry
-
NCT01398592 -
2011-000518-21
-
- Other papers using this trial's data
- Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Germany
- Registry status
- Completed
Technical summary
Registry record NCT01398592. Randomized; no masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2012-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy
- Acronym
- FPG-VISIT
- Condition
- Diabetes Mellitus Type 2
- Intervention (Drug)
- Vildagliptin
- Intervention (Drug)
- Sitagliptin
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01398592- Content hash
9cf0600b2c3b60c584ad86509978f5ee0f9f444d06d3007f947e95dd51371b74